GE HealthCare
GEHC
$66.01
+2.07%
GE HealthCare Technologies Inc. is a leading global medical technology company operating in the Healthcare sector, specifically within Medical - Healthcare Information Services. Its core business encompasses the development and manufacturing of medical imaging and ultrasound equipment, advanced visualization solutions, patient care solutions, and pharmaceutical diagnostics. The company is a market leader in imaging and ultrasound, leveraging its heritage from General Electric to maintain a strong competitive position with a geographically diverse revenue base and an estimated 50% recurring revenue stream from service, diagnostics, and digital solutions. The current investor narrative is dominated by concerns over profitability and guidance, as evidenced by a recent sharp stock price decline following the company's lowered 2026 earnings outlook due to significant cost inflation pressures that its long sales cycles make difficult to mitigate quickly.…
GEHC
GE HealthCare
$66.01
Related headlines
Investment Opinion: Should I buy GEHC Today?
Rating & Thesis: Hold. GEHC is a fundamentally sound company in a painful transition, where deep valuation and strong cash flow are offset by severe near-term earnings headwinds and poor price momentum. The consensus analyst stance is cautiously bullish with a $81.10 target, but the stock lacks a clear near-term catalyst for re-rating.
Supporting Evidence: The stock trades at a compelling forward P/E of 11.89x, a 34% discount to its trailing multiple, suggesting low expectations. However, revenue is contracting (-12.13% YoY in Q4) and profitability is under severe pressure (net margin fell 960 bps YoY). The 27% upside to the average analyst target is attractive, but it hinges on achieving the $6.82 EPS estimate amidst significant cost challenges. The strong TTM FCF of $1.506B and ROE of 20.08% provide a solid financial floor.
Risks & Conditions: The two biggest risks are 1) further margin erosion from persistent inflation, and 2) a failure to stabilize top-line revenue. This Hold rating would upgrade to a Buy if the forward P/E compresses further below 10x without a deterioration in FCF, or if management provides concrete evidence of mitigating cost pressures in the next earnings report. It would downgrade to a Sell if revenue decline accelerates beyond 15% YoY or if FCF generation meaningfully weakens. Relative to its history and the sector, the stock is fairly valued to slightly undervalued given the current risk profile.
Sign up to view all
GEHC 12-Month Price Forecast
The investment case for GEHC is a clash between valuation and fundamentals. The stock is cheap on a forward earnings basis and generates exceptional cash flow, but the near-term operational picture is deteriorating rapidly. The base case of a slow, grinding recovery is most probable, but the path is fraught with execution risk. The stance would upgrade to bullish on evidence of margin stabilization in the next quarterly report, specifically if operating income holds above $650M on stable revenue. It would turn bearish if free cash flow shows signs of weakening or if the stock decisively breaks below $58.75 support.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GE HealthCare's 12-month outlook, with a consensus price target around $85.81 and implied upside of +30.0% versus the current price.
Average Target
$85.81
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$53 - $86
Analyst target range
GEHC is covered by 9 analysts, indicating a moderate level of institutional interest. The consensus sentiment leans bullish, with recent actions from firms like BTIG, Wells Fargo, Stifel, and Evercore ISI maintaining 'Buy' or 'Overweight' ratings, while others like Citigroup, Barclays, and Morgan Stanley hold 'Neutral' or 'Equal Weight' stances. The average target price implied by the consensus EPS estimate of $6.82 and the forward P/E of 11.89x is approximately $81.10, representing a potential upside of about 27% from the current price of $63.81. The target range is relatively tight, with a low EPS estimate of $6.71 and a high of $6.90, suggesting analysts have a fairly unified view on near-term earnings potential despite the stock's volatility. The high target likely assumes successful management of cost inflation and a stabilization in the core imaging business, while the low target may be pricing in further margin compression or competitive pressures. The recent cluster of analyst activity in February 2026, coinciding with earnings, shows no downgrades, indicating the guidance cut was largely anticipated and may be viewed as a temporary setback rather than a permanent impairment of the business model.
Bulls vs Bears: GEHC Investment Factors
The bear case currently holds stronger evidence, anchored by a severe 74% YoY earnings collapse and a significant guidance reduction driven by unmitigated cost inflation. The bull case rests on a deep valuation discount and strong free cash flow, suggesting the bad news may be priced in. The single most important tension in the investment debate is whether GEHC's operational model can adapt to persistent cost pressures before its strong financial foundation (FCF, ROE) erodes. If management demonstrates an ability to protect margins through pricing or efficiency, the stock's low valuation could provide a powerful rebound. If not, the earnings decline may continue, justifying the current pessimism.
Bullish
- Deep Valuation Discount: The stock trades at a forward P/E of 11.89x, a significant discount to its trailing P/E of 17.97x and near historical lows. This embeds substantial pessimism, offering a value entry point if earnings stabilize.
- Strong Free Cash Flow Generation: The company generated $1.506 billion in TTM free cash flow, providing ample financial flexibility. This robust cash flow supports debt service, capital returns, and investment despite earnings pressure.
- High Analyst Target Upside: The consensus analyst target price is approximately $81.10, implying a 27% upside from the current $63.81. This target is based on a forward EPS of $6.82, suggesting confidence in a recovery.
- Defensive, Recurring Revenue Base: An estimated 50% of revenue is recurring from service, diagnostics, and digital solutions. This provides stability and offsets some cyclicality in equipment sales, as seen in the strong 54.3% Q4 gross margin.
Bearish
- Severe Earnings Contraction & Guidance Cut: Q4 2025 net income collapsed 74% YoY to $184M, with net margin compressing from 13.54% to 3.94%. Management cut 2026 guidance citing $250M in cost inflation, a fundamental deterioration.
- Revenue Deceleration and Decline: Q4 2025 revenue fell 12.13% YoY to $4.674B, continuing a sequential decline from Q3's $5.143B. This top-line contraction signals weakening demand or competitive pressures in its core imaging business.
- Pronounced Technical Downtrend: The stock is down 25.33% over six months and 10.29% over the past year, underperforming the SPY by 26.68 percentage points over three months. It trades 29% below its 52-week high, indicating sustained selling pressure.
- Operational Inflexibility to Inflation: Long sales cycles make it difficult to quickly offset $250M in cost inflation, as noted in recent news. This structural issue pressures margins and creates uncertainty around near-term profitability.
GEHC Technical Analysis
GEHC is in a pronounced downtrend, having declined 10.29% over the past year and 25.33% over the past six months. The stock is currently trading at $63.81, which places it near the lower end of its 52-week range, approximately 29% above its 52-week low of $58.75 and 29% below its 52-week high of $89.77. This positioning suggests the stock is in a value-oriented zone but remains under significant selling pressure, having failed to sustain a recovery from its April lows. The short-term momentum is mixed; the stock is up 4.54% over the past month, showing tentative signs of stabilization, but this is overshadowed by a 14.08% decline over the past three months. This divergence indicates the recent uptick is a minor bounce within a larger bearish trend, lacking the strength to signal a reversal, especially as it has underperformed the SPY by 26.68 percentage points over the same three-month period. Key technical support is clearly defined at the 52-week low of $58.75, with major resistance at the 52-week high of $89.77. A sustained break below $58.75 would signal a continuation of the downtrend, while a move above the recent high near $88 from January would be needed to suggest a trend change. The stock's beta of 0.868 indicates it is slightly less volatile than the broader market, which has not shielded it from severe underperformance, as evidenced by a -37.33 relative strength reading versus the SPY over the past year.
Beta
0.86
0.86x market volatility
Max Drawdown
-32.5%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
-7.9%
Cumulative gain past year
| Period | GEHC Return | S&P 500 |
|---|---|---|
| 1m | +4.0% | -0.1% |
| 3m | -9.1% | +9.0% |
| 6m | -23.3% | +7.0% |
| 1y | -7.9% | +22.9% |
| ytd | -20.3% | +8.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GEHC Fundamental Analysis
GEHC's revenue trajectory shows concerning signs of deceleration and contraction. For Q4 2025 (ending December 31), revenue was $4.674 billion, representing a year-over-year decline of 12.13%. This follows a sequential decline from Q3 2025 revenue of $5.143 billion and Q2 2025 revenue of $5.006 billion, indicating a clear downward trend in top-line performance as the year progressed. The company's largest segment, Imaging, generated $4.901 billion, but without a percentage, the exact growth driver or drag is unclear, though the overall trend points to broad-based pressure. Profitability has been significantly impacted, with net income for Q4 2025 falling sharply to $184 million, a stark drop from $720 million in Q4 2024. The gross margin for the quarter was 54.3%, which is historically strong, but the operating income of $664 million on $4.674 billion in revenue translates to an operating margin of approximately 14.2%, showing pressure on the bottom line. The quarterly net margin of 3.94% is a significant compression from the 13.54% net margin in Q4 2024. The balance sheet and cash flow position show a mixed picture of financial health. The company's debt-to-equity ratio stands at 0.96, indicating a moderate but manageable level of leverage. The current ratio is 1.18, suggesting adequate short-term liquidity. Importantly, the company generated robust free cash flow of $1.506 billion on a trailing twelve-month basis, which provides significant financial flexibility to fund operations, service debt, and return capital to shareholders. The return on equity (ROE) of 20.08% remains strong, indicating efficient use of shareholder capital despite recent earnings headwinds.
Quarterly Revenue
$4.7B
2025-12
Revenue YoY Growth
-0.12%
YoY Comparison
Gross Margin
+0.54%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GEHC Overvalued?
Given GEHC's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The stock currently trades at a trailing P/E of 17.97x and a forward P/E of 11.89x. The substantial discount of the forward multiple suggests the market has significantly lowered its earnings expectations for the coming year, likely in response to the recent guidance cut. Compared to industry averages, GEHC's trailing P/E of 17.97x appears to be at a discount to the broader healthcare technology sector, which often trades at higher multiples for growth, but this discount is justified given the company's recent earnings contraction and guidance reduction. The stock's Price-to-Sales (P/S) ratio of 1.82 and Enterprise Value-to-Sales (EV/Sales) of 1.75 further indicate a valuation that is not demanding relative to its revenue base. Historically, GEHC's valuation has compressed significantly from its post-spinoff levels. Its current trailing P/E of 17.97x is near the lower end of its observable historical range, which has seen ratios above 50x in late 2025 during stronger earnings periods and as low as 11.96x in late 2022. Trading near historical lows suggests the market is pricing in substantial pessimism, potentially creating a value opportunity if the company can navigate its current cost challenges, but also reflecting real fundamental deterioration.
PE
18.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 12x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is continued margin compression from unmanaged cost inflation, which drove a 74% YoY drop in Q4 net income. With long sales cycles limiting pricing flexibility, the $250M headwind cited in guidance could persist, further pressuring the already compressed 3.94% quarterly net margin. Revenue concentration in the Imaging segment (45% of sales) and geographic exposure to China (11% of sales) add cyclical and geopolitical risks to the top line, which is already contracting at a 12.13% YoY rate. While the debt-to-equity of 0.96 is moderate, it compounds interest expense risk in a higher-rate environment.
Market & Competitive Risks: The stock trades at a forward P/E of 11.89x, a discount that reflects lowered expectations but could compress further if earnings disappoint again. Competitive disruption is a tangible threat, as evidenced by news of rival RadNet's $270M AI acquisition, highlighting the industry's shift towards advanced diagnostics where GEHC must invest to maintain its leadership. The stock's beta of 0.868 suggests it is less volatile than the market, yet it has dramatically underperformed (down 25.33% in 6 months vs. SPY up 10.41%), indicating severe company-specific de-rating risk that may not be over.
Worst-Case Scenario: The worst-case involves a failure to contain cost inflation, leading to consecutive earnings misses, analyst downgrades, and a loss of investor confidence in the 2026 guidance. This could trigger a re-test and break of the key $58.75 technical support (the 52-week low), leading to a valuation derating towards the bear-case analyst EPS low of $6.71 applied to a single-digit P/E. From the current price of $63.81, a realistic downside in this adverse scenario is a decline of 20-25%, towards the $48-$51 range, representing a loss comparable to the stock's maximum drawdown of -32.53%.
FAQ
The key risks are, in order of severity: 1) Operational: Persistent cost inflation eroding margins, as evidenced by the $250M headwind and compressed 3.94% net margin. 2) Fundamental: Continued revenue decline, with Q4 sales down 12.13% YoY. 3) Competitive: Rivals like RadNet investing heavily in AI, threatening GEHC's leadership in advanced diagnostics. 4) Financial: Moderate leverage (D/E of 0.96) in a rising rate environment, though mitigated by strong $1.5B FCF.
The 12-month forecast is bifurcated. The base case (55% probability) sees a slow grind to the $70-$80 range as the company meets lowered earnings guidance. The bull case (25%) targets $81-$89 on a successful margin recovery. The bear case (20%) risks a fall to $58-$65 if problems worsen. The most likely outcome is the base case, predicated on the assumption that management's $6.82 EPS estimate for 2026 is achievable, but with limited multiple expansion due to ongoing skepticism.
GEHC appears fairly valued to slightly undervalued relative to its current risk profile. The forward P/E of 11.89x is a steep discount to its trailing multiple of 17.97x and suggests the market expects depressed earnings. The P/S ratio of 1.82 is not demanding. However, this discount is justified by the 74% YoY drop in Q4 net income. The valuation implies the market expects prolonged profitability challenges, making it a discount for a reason rather than a clear bargain.
GEHC presents a high-risk, high-potential-reward opportunity. It is not a good buy for conservative investors or those seeking stable growth, given its 25% six-month decline and severe earnings contraction. However, for value investors comfortable with volatility, the 27% upside to analyst targets and a forward P/E of 11.89x could be compelling if they believe management can eventually overcome its $250M cost inflation challenge. The decision hinges entirely on one's conviction in a margin recovery.
GEHC is unsuitable for short-term trading due to its negative momentum and lack of near-term catalysts. It is a candidate for a long-term (3+ year) value investment, where an investor bets on the company's strong market position and cash flow generation ultimately overcoming its current operational woes. The low beta of 0.868 and minimal dividend yield (0.17%) further support a long-term, capital-appreciation-oriented holding period to allow the turnaround thesis to play out.